Lei Zhu1, Jie Zhang1, Alexander Marx1, Christel Weiss1, Wen-Tao Fang1. 1. 1 Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200032, China ; 2 Institute of Pathology, 3 Department of Medical Statistics and Biomathematics, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany ; 4 Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200032, China.
Abstract
BACKGROUND: To assess the correlation of WHO histological classification of thymomas and thymic carcinomas (TCs) with prognosis in recently treated patient cohort compared to a historical one from a single institution. METHODS: Retrospective review of clinical charts and histological sections of 241 patients treated during 1997-2004. Univariate and multivariate analysis of associations between risk factors including gender, age, tumor size, myasthenia gravis, WHO histological subtype, Masaoka stage, resection status, (neo-)adjuvant therapies, and survival. RESULTS: The 5-year overall survival (OS) of A, AB, B1, B2, B3 thymomas and TCs patients was 100%, 100%, 94%, 80%, 94% and 45%. Five-year progression-free survival (PFS) was 100%, 96%, 78%, 80%, 78% and 39%, respectively. The 5-year OS of patients with Masaoka stage I, II, III and IV thymomas and TCs was 96%, 89%, 59% and 50%. (Neo-)adjuvant therapies were administered more often than in the historical cohort. Tumor-related death mainly occurred in patients with stage III, IV and B2, B3 thymomas and TCs. By univariate analysis, gender, tumor size, myasthenia gravis (MG) status, histotype, Masaoka stage, resection status and treatment were associated with OS. By multivariate analysis, histological subtype, Masaoka stage, and (neo-)adjuvant therapy were revealed as independent prognostic indicators. CONCLUSIONS: WHO histological subtype, Masaoka stage and (neo-)adjuvant treatment have remained independent determinants of OS in patients with thymomas and TCs. Compared with the historical cohort during 1969-1996, prognosis of patients with B2, B3 thymomas has improved, which may be partly due to the increased use of adjuvant therapies. Prognosis of patients with TCs remained unsatisfactory, suggesting that neoadjuvant treatment should be tested to improve survival.
BACKGROUND: To assess the correlation of WHO histological classification of thymomas and thymic carcinomas (TCs) with prognosis in recently treated patient cohort compared to a historical one from a single institution. METHODS: Retrospective review of clinical charts and histological sections of 241 patients treated during 1997-2004. Univariate and multivariate analysis of associations between risk factors including gender, age, tumor size, myasthenia gravis, WHO histological subtype, Masaoka stage, resection status, (neo-)adjuvant therapies, and survival. RESULTS: The 5-year overall survival (OS) of A, AB, B1, B2, B3 thymomas and TCs patients was 100%, 100%, 94%, 80%, 94% and 45%. Five-year progression-free survival (PFS) was 100%, 96%, 78%, 80%, 78% and 39%, respectively. The 5-year OS of patients with Masaoka stage I, II, III and IV thymomas and TCs was 96%, 89%, 59% and 50%. (Neo-)adjuvant therapies were administered more often than in the historical cohort. Tumor-related death mainly occurred in patients with stage III, IV and B2, B3 thymomas and TCs. By univariate analysis, gender, tumor size, myasthenia gravis (MG) status, histotype, Masaoka stage, resection status and treatment were associated with OS. By multivariate analysis, histological subtype, Masaoka stage, and (neo-)adjuvant therapy were revealed as independent prognostic indicators. CONCLUSIONS: WHO histological subtype, Masaoka stage and (neo-)adjuvant treatment have remained independent determinants of OS in patients with thymomas and TCs. Compared with the historical cohort during 1969-1996, prognosis of patients with B2, B3 thymomas has improved, which may be partly due to the increased use of adjuvant therapies. Prognosis of patients with TCs remained unsatisfactory, suggesting that neoadjuvant treatment should be tested to improve survival.
Authors: Cameron D Wright; John C Wain; Daniel R Wong; Dean M Donahue; Henning A Gaissert; Hermes C Grillo; Douglas J Mathisen Journal: J Thorac Cardiovasc Surg Date: 2005-10-13 Impact factor: 5.209
Authors: Rohit K Jain; Rutika J Mehta; John D Henley; Kenneth A Kesler; Patrick J Loehrer; Sunil Badve Journal: Mod Pathol Date: 2010-09-10 Impact factor: 7.842
Authors: Ralf J Rieker; Josef Hoegel; Alicia Morresi-Hauf; Walter J Hofmann; Hendrik Blaeker; Roland Penzel; Herwart F Otto Journal: Int J Cancer Date: 2002-04-20 Impact factor: 7.396
Authors: Philipp Ströbel; Andrea Bauer; Bernhard Puppe; Til Kraushaar; Axel Krein; Klaus Toyka; Ralf Gold; Michael Semik; Reinhard Kiefer; Wilfred Nix; Berthold Schalke; Hans Konrad Müller-Hermelink; Alexander Marx Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544
Authors: Gang Chen; Alexander Marx; Wen-Hu Chen; Jiang Yong; Bernhard Puppe; Philipp Stroebel; Hans Konrad Mueller-Hermelink Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Alberto M Marchevsky; Ruta Gupta; Robert J McKenna; Mark Wick; Cesar Moran; Maureen F Zakowski; Saul Suster Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: E T Verghese; M A den Bakker; A Campbell; A Hussein; A G Nicholson; A Rice; B Corrin; D Rassl; G Langman; H Monaghan; J Gosney; J Seet; K Kerr; S K Suvarna; M Burke; P Bishop; S Pomplun; S Willemsen; B Addis Journal: Histopathology Date: 2008-08 Impact factor: 5.087
Authors: Magdalena Knetki-Wróblewska; Dariusz M Kowalski; Marta Olszyna-Serementa; Maciej Krzakowski; Małgorzata Szołkowska Journal: Thorac Cancer Date: 2021-01-02 Impact factor: 3.500